Cariad Chester

Cariad Chester

Cariad Chester is a member of Obsidian’s Board of Directors and a Partner at The Column Group Crossover Fund (TCG X). Prior to joining TCG X, Cariad was a Managing Director at Aquilo Capital, where he led investments in biotechnology companies developing human therapeutics. Prior to Aquilo Capital, he served as a research scientist in the lab of Dr. Holbrook Kohrt at Stanford University. His research focused on understanding tumor-immune system interactions during cancer onset, progression, and treatment. He has authored or co-authored over 20 peer-reviewed manuscripts and presented research at conferences in Canada, the US, and China. Cariad has also worked in clinical trial management, helping to launch and coordinate phase I, first-in-human trials of investigational immunotherapeutic agents, and formerly operated a consulting practice advising early-stage companies on assay development and pipeline prioritization. Cariad received his B.A. from Swarthmore College, where he double majored in Neuroscience and Comparative Religious Studies.



< Back to Board